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Brief Definit ive Report
The search for the cause of autism spectrum 
disorder (ASD) revealed the disease’s associations 
with numerous gene mutations. Many of the 
ASD candidate genes encode proteins that con-
trol neuronal network formation and function 
(Chen et al., 2015). A significant fraction of 
ASD-associated genes, however, encode rather 
ubiquitous regulators of gene expression (De 
Rubeis et al., 2014). The latter finding under-
scores the possibility of an epigenetic etiology 
of ASD, where aberrant control of gene expres-
sion rather than gene mutations can lead to ab-
normal neuronal development and function.
One of the major challenges for testing the 
role of abnormal gene regulation in brain func-
tion is the lack of experimental models where 
changes in gene expression can be achieved in 
a controlled fashion and without the general-
ized negative impact on neuronal development, 
survival, and function. This obstacle could be 
potentially overcome by using brain-permeable 
compounds that regulate transcription in a selec-
tive and time-dependent fashion. Pharmacologi-
cal suppression of well-defined transcriptional 
processes would allow one to determine the im-
pact of acute or chronic transcriptional deregu-
lation on animal behavior at any developmental 
time point and would also enable the identifi-
cation of genes affected by the temporal im-
pairment of these processes.
Our earlier studies describe the pharmaco-
logical modulation of transcription by inhibi-
tors of the bromodomain and extraterminal 
domain–containing proteins (BETs; Nicodeme 
et al., 2010). In humans and mice, somatic cells, 
including neurons, express three independent 
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Studies investigating the causes of autism spectrum disorder (ASD) point to genetic, as 
well as epigenetic, mechanisms of the disease. Identification of epigenetic processes that 
contribute to ASD development and progression is of major importance and may lead to 
the development of novel therapeutic strategies. Here, we identify the bromodomain and 
extraterminal domain–containing proteins (BETs) as epigenetic regulators of genes in-
volved in ASD-like behaviors in mice. We found that the pharmacological suppression of 
BET proteins in the brain of young mice, by the novel, highly specific, brain-permeable 
inhibitor I-BET858 leads to selective suppression of neuronal gene expression followed by 
the development of an autism-like syndrome. Many of the I-BET858–affected genes have 
been linked to ASD in humans, thus suggesting the key role of the BET-controlled gene 
network in the disorder. Our studies suggest that environmental factors controlling BET 
proteins or their target genes may contribute to the epigenetic mechanism of ASD.
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of 1,000 potential brain-penetrant BET inhibitor compounds, 
we identified the novel tetrahydroquinoline class (THQ; 
Gosmini et al., 2014) compound I-BET858 (Fig. 1 A). 
I-BET858 displayed an appropriate profile for progression 
into in vivo rodent models based on its calculated physico-
chemical properties, pharmacokinetics, BET inhibitory activity 
in cell-based assays, and enhanced brain penetrance (Fig. S1, 
A and B). The binding mode of I-BET858 to BRD4-BD1 
was determined by x-ray crystallography (Fig. 1 B and Fig. S1, 
C and D). The curvature of the THQ template complements 
that of the BET proteins and results in high affinity of 
I-BET858 for the BET subfamily with >1,000-fold selectivity 
over 34 other bromodomain-containing proteins (Fig. S2).
Selective impairment of neuronal gene expression  
by pharmacological BET inhibition in vitro
The impact of I-BET858 on neuronal gene expression was 
initially assessed in vitro. Primary cortical neurons isolated 
from E18 mouse brain were grown in an in vitro culture sys-
tem for 7 d, followed by treatment with I-BET858 at a con-
centration of 1 µM. As in other cell types treated with I-BET 
or JQ1 (Nicodeme et al., 2010; Dawson et al., 2011; Delmore 
et al., 2011), the treatment of primary cultured neurons with 
I-BET858 leads to a time-dependent up- and down-regulation 
of numerous genes (Fig. 1, C and D). Opposite to gene in-
duction, the down-regulation of gene expression by BET 
inhibitors has been shown to correlate directly with BET- 
association at the gene loci before the BET inhibitor treat-
ment and loss of BET-association following exposure to 
the inhibitors (Nicodeme et al., 2010). Therefore, in our stud-
ies we focus exclusively on genes that are suppressed by 
I-BET858.
Treatment of primary cortical neurons with I-BET858 
results in time-dependent changes in gene expression, character-
ized by the moderate (2.75-fold, on average) down-regulation 
of 225 and 1,158 genes at 2 and 12 h after I-BET858 treat-
ment, respectively (Fig. 1, C and D, and Table S1). Notably, 
I-BET858 preferentially affects genes controlling synaptic 
transmission, neuronal development, and morphogenesis 
(Fig. 1 E). Moreover, 10% of the suppressed genes (118/1,158; 
P < 0.0001; OR, 2.486) are previously identified ASD risk 
genes (combined lists from Basu et al. [2009] and King et al. 
[2013]) in humans (Fig. 1 F and Table S1). Several of the ASD 
candidate genes that show strong suppression in response to 
I-BET858, such as Met, Gabra1, Cntn6, Pde4b, Npas2, Cdh10, 
and Foxp1, have been shown to play an important role in 
neuronal development and function in circuits relevant to 
core behavioral domains of ASD (Zhou et al., 1997; Qiu et al., 
2014; Bacon et al., 2015; Ozburn et al., 2015). The brain-
specific deficiency of Foxp1-expression was recently shown 
to impair neuronal development, causing autistic-like behav-
iors in mice (Bacon et al., 2015).
The ability of I-BET858 to modify gene expression in 
neurons was further demonstrated by the profound yet selec-
tive effect of I-BET858 on the expression of genes induced 
by the brain-derived neurotrophic factor (BDNF; Fig. 2, 
BET proteins: Brd2, Brd3, and Brd4 (Sanchez et al., 2014). 
All three BET proteins contain two N-terminal bromodo-
mains (BD1 and BD2) that recognize acetylated lysines within 
the N-terminal domain of histone H4, as well as other lysine-
acetylated proteins (Filippakopoulos and Knapp, 2012). The 
binding of the BET bromodomain to acetylated histone H4 
lysines initiates a chain of biochemical and molecular events 
that leads to the formation of elongation-competent tran-
scriptional complexes containing RNA Polymerase II phos-
phorylated at serine 2 (Brès et al., 2008). Pharmacological 
inhibitors of BET proteins, such as I-BET (Nicodeme et al., 
2010) or JQ1 (Filippakopoulos et al., 2010), bind with high 
specificity to the acetyl-lysine–binding pocket of the tandem 
bromodomains of all members of the BET family. The in-
hibitor binding prevents BET protein association with acety-
lated histone H4 and affects gene transcription (Nicodeme 
et al., 2010; Barbieri et al., 2013). However, despite the 
widespread BET binding to numerous genes, the impact of 
the BET inhibitors on gene expression in various cell types is 
surprisingly limited (Nicodeme et al., 2010; Dawson et al., 
2011; Delmore et al., 2011). The mechanism of the selective 
impact of BET inhibitors on gene expression is not well un-
derstood. Our earlier studies showed that susceptibility to 
I-BET in activated macrophages correlates with the gene’s 
dependence on SWI/SNF-mediated chromatin remodeling 
(Nicodeme et al., 2010). Other studies have suggested a link 
between the susceptibility to BET inhibitors and BET- 
association with specific enhancer clusters (super-enhancers; 
Lovén et al., 2013).
To address the impact of BET suppression on neuronal 
gene expression and brain function, we developed a novel, 
brain-permeable I-BET (I-BET858). Here, we provide evi-
dence for the selective impact of BET protein functions on 
neuronal gene expression in vitro and in vivo. We show that 
I-BET858 treatment preferentially suppresses genes associ-
ated with neuronal differentiation and synaptic function and 
has no effect on neuronal housekeeping or early response 
genes. The suppressive effects of I-BET858 correlate di-
rectly with gene length. A significant number of I-BET858–
suppressed genes, including genes of extended length, are 
potential ASD candidate genes in humans (Basu et al., 2009; 
King et al., 2013). Furthermore, suppression of specific neu-
ronal genes by I-BET858 in young mice leads to the develop-
ment of an autism-like syndrome. Our findings describe for 
the first time a pharmacologically induced model of ASD 
and point to the selective I-BET858 suppressed genes as 
potential key contributors to ASD in mice.
RESULTS AND DISCUSSION
Identification of a novel brain-permeable BET inhibitor
Brain permeability is a crucial factor in assessing the impact of 
BET inhibitors on neuronal gene expression and associated 
behaviors. To investigate the effects of BET inhibition within 
the central nervous system, we identified a novel BET inhib-
itor compound with higher brain permeability than the origi-
nal I-BET151 and I-BET762. Through in silico assessment 
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In contrast, the expression of IEGs, such as Arc, Dusp1/4, 
Egr1-4, Fosb, Homer1, Ier2/5, Junb, Nr4a1/2/3, and Srf in re-
sponse to BDNF treatment after 2 and 12 h was not affected 
or even slightly increased by I-BET858 (Fig. 2, A–C). These 
data suggest that I-BET858 treatment in neurons does not 
disrupt BDNF-induced neuronal signal responses or subse-
quent IEG induction, but specifically represses the transcrip-
tion of a selected group of secondary/late response genes in 
response to BDNF treatment (Fig. 2, A–C).
Selective impairment of neuronal gene expression  
by pharmacological BET inhibition in vivo
The development of the brain-permeable I-BET858 enables 
us to address for the first time the impact of pharmacological 
suppression of BET proteins on gene expression in neurons 
in vivo. We found that I-BET858 enters the mouse brain 
shortly after an i.p. injection (Fig. S1 B). A single acute i.p. 
administration of I-BET858 at 30 mg/kg allows I-BET858 
detection in the brain at a concentration of ≥1 µM lasting for 
several hours after the injection (Fig. S1 B). The tissue concen-
tration of 1 µM matches the concentration of I-BET required 
for the therapeutic impact during systemic inflammation 
(Nicodeme et al., 2010).
In our initial studies, we addressed the impact of acute 
and chronic I-BET858 administration on gene expression 
in the striatum. We chose the striatum because of (a) its rel-
atively homogenous neuronal population with 90% of stria-
tal neurons being D1 or D2 receptor-expressing medium 
spiny neurons, (b) the well-known pattern of medium spiny 
A and B). The BDNF-controlled genes play a crucial role 
during brain development and are essential for normal neu-
ronal function and survival (Park and Poo, 2013). Treatment 
of primary cortical neurons with BDNF results in the induc-
tion of numerous genes that regulate neuronal maturation, 
axogenesis, synapse formation and synaptic transmission in 
neurons (Table S2). The BDNF-induced transcriptional 
changes follow a well-defined temporal pattern with the in-
duction of early response genes, such as Egr1-4, Fos, FosB, 
Ier2-5, Jun, JunB, and Nr4a2/3, within 20 min after BDNF 
stimulation. The expression of these immediate-early genes 
(IEGs) is followed by the induction of secondary/late re-
sponse genes that control the specific BDNF-induced changes 
in neuronal morphology and function (Alder et al., 2003; 
Calella et al., 2007).
We found that treatment with I-BET858 at 1 µM re-
sulted in a highly selective and time-dependent suppression 
of gene expression in BDNF-stimulated cortical neurons 
(Fig. 2, A and B). I-BET858 has no impact on housekeep-
ing gene expression but specifically affects the expression of 
a selected group of BDNF-induced neuronal genes at 2 and 
12 h after BDNF treatment (Fig. 2, A–C; and Table S2). 
Many BDNF-inducible and I-BET858–suppressed genes 
are regulators of important neuronal processes, including 
neuronal transmission via ion channels (such as Cacna2d1, 
Kcnma1, and Kcna1/4), neurotransmitter receptor signaling 
(Drd1a, Gabra1, Gria1-3, Grin3a, and Pde1c/4d), and den-
drite and axon development (Ank3, Bdnf, Camk2d, Dscaml1, 
Dclk1, Ntrk3, and Sema3a; Fig. 2, A–C).
Figure 1. Effect of the brain-permeable inhibitor of BET proteins (I-BET858) on gene expression in primary neurons in vitro. (A) Chemical 
structure of I-BET858. (B) X-ray structure of I-BET858 (blue) bound to the acetylated lysine (Kac) recognition pocket of BRD4-BD1 (red spheres, water 
network; yellow dashed lines, hydrogen bonds). The WPF shelf (W81, P82, F83), as well as the asparagine N140 essential for acetylated lysine (Kac) bind-
ing, are labeled accordingly. (C and D) Gene expression in primary cortical neurons treated with I-BET858 (1 µM) for 2 and 12 h was analyzed using mi-
croarray analysis (n = 3/group, experiment was performed in duplicate). (C) Volcano plot shows the genes that are significantly suppressed (P < 0.05; 
>2-fold; blue) or induced (red) after I-BET858 treatment. (D) Bar graph shows the number and fold gene expression changes. (E) Gene Ontology (GO)  
enrichment of I-BET858–induced (top) or suppressed (bottom) genes (log10 p-value; red line, P = 0.05). (F) Venn diagram shows the overlap between  
I-BET858–suppressed genes and ASD-associated genes. Statistics: 2 test, ***, P < 0.0001; OR, 2.486.
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Acute I-BET858 treatment results in the suppression 
of 270 genes 4 h after a single i.p. injection (Fig. 3 A and 
Table S3). The chronic administration of I-BET858 for 
2 wk does not affect the total number, but rather the 
pattern of affected genes (Fig. 3, B and C; and Table S3). 
neuron gene expression (Heiman et al., 2008), (c) the well-
established role of the striatum in animal behavior, and 
(d) the contribution of impaired striatal function to neuro-
nal disorders, including ASD (Di Martino et al., 2011; Peça 
et al., 2011; Rothwell et al., 2014).
Figure 2. I-BET858 effect on BDNF-inducible gene expression in vitro. Heat maps show normalized expression values using microarray analysis 
for all BDNF-inducible and I-BET–suppressed (left, more than twofold) or I-BET–resistant (right) genes in cortical neurons at 2 h (A) and 12 h (B) after 
treatment (n = 3/group; experiment was performed in duplicate). Selected genes are indicated. Circle plot shows the number of BDNF-inducible genes 
that are unchanged (white), significantly suppressed (blue), or induced (red) more than twofold after I-BET858 treatment. Bar graphs display selected GO 
enrichments (log10 p-value; red line, P = 0.05). (C) I-BET858 effect on the expression of selected immediate-early (left) or secondary (middle) BDNF-
inducible genes or housekeeping genes (right) is shown.
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extra-long genes >100 kb with a correlation between gene 
length and reduced expression (Fig. 4 A; Pearson’s r = 0.147877; 
P < 0.0001). The average gene length of I-BET858–suppressed 
genes is 130 kb and exceeds the average length of genes 
(50 kb) expressed in these neurons by 2.5-fold (Fig. 4 B). 
Notably, 20% of the I-BET858–suppressed genes (194/1,158) 
are extremely long genes that range in length from 200–
2,000 kb (Table S4). In accordance with previous data point-
ing to a possible correlation between extra-long gene length 
and human ASD risk genes (King et al., 2013), we found 
that 42 of the 100 longest I-BET858–repressed genes are 
potential ASD candidate genes (P < 0.0001; OR, 15.44; 
Table S4).
A similar correlation between gene length and suscepti-
bility to I-BET858–mediated transcriptional suppression is 
observed in BDNF-treated neurons (Fig. 4, C and D). BDNF 
treatment leads to a slight increase in the expression of long 
genes (>100 kb) that are also strongly and specifically suppressed 
by I-BET858 treatment (Fig. 4 C; Pearson’s r = 0.119946; 
P = 0.004). The gene length of I-BET858 suppressed genes 
is approximately threefold higher than the average length of 
genes expressed in these neurons (Fig. 4 D, Table S4).
The strong correlation between gene length and I-BET858 
susceptibility is also observed in vivo (Fig. 4 E). Similar to 
in vitro–cultured neurons, I-BET858 affected gene transcripts 
in the mouse brain in vivo are on average approximately two-
fold longer than those induced or unaffected by I-BET858 
(Fig. 4 F and Table S4). Furthermore, 18 (acute) and 13 (chronic) 
of the 100 longest I-BET858–repressed genes in vivo are 
ASD candidate genes (P < 0.0001; OR, 4.428; P < 0.001; 
OR, 3.001). These genes include the transcriptional regula-
tors Foxp1, Npas2, Phf2, Setbp1, Tcf3, and Zbtb20, and the 
neuronal signaling and adhesion proteins Antxr1, Cdh10, 
Cdh11, Grm1, Lamb1, Nrg1, and Slitrk5, many of which are 
Approximately 45% of genes suppressed by acute I-BET858 
treatment remain down-regulated 12 h after chronic daily 
I-BET858 injections, whereas 155 genes are suppressed by 
I-BET858 only after long-term treatment (Fig. 3 C; P < 0.0001; 
OR, 124.8). A significant fraction of the in vivo I-BET858–
suppressed genes (69/270 after acute; 51/274 after chronic; 
P < 0.0001; OR, 7.701 and 5.042) overlap with the I-BET–
repressed genes in primary neurons in vitro (Table S3). Most 
importantly, acute and chronic I-BET858 treatment results in 
significant down-regulation of 34 genes that have been previ-
ously implicated in ASD (P = 0.0025; OR, 1.755). Several of 
the I-BET858–suppressed ASD-associated genes include po-
tent transcriptional regulators, such as the histone lysine de-
methylase Phf2, the Set-domain binding protein Setbp1, and 
the transcription factors Foxp1, Nr4a2, Zbtb20, and Tcf3 
(Table S3). The latter finding points to BET proteins as tran-
scriptional regulators of gene-controlling chromatin circuits 
that can broaden the impact of BET inhibition on gene ex-
pression in neurons. This may, in part, explain the distinct pat-
terns of genes only altered with chronic dosing (Fig. 3 C). 
Similar to our in vitro studies, in vivo administration of 
I-BET858 has no impact on housekeeping gene expression 
(not depicted) but preferentially suppresses genes involved in 
neuronal development, and dendrite and synapse formation 
and function (Fig. 3 B).
I-BET858–mediated gene suppression correlates  
with gene length
Earlier studies revealed a link between gene length and human 
ASD risk genes (King et al., 2013; Gabel et al., 2015). Re-
markably, many of the genes suppressed by I-BET858 are 
on average significantly longer than the unaffected genes 
(Fig. 4). Treatment with I-BET858 for 12 h, but not for 2 h, of 
in vitro–cultured, nonstimulated neurons suppresses preferentially 
Figure 3. Selective effect of I-BET858 on gene expression in vivo. Volcano plots show genes that are significantly suppressed (blue) or induced 
(red) more than twofold after acute (A) or chronic (B) I-BET858 treatment in the mouse striatum using RNA sequencing analysis (n = 2). Bar graphs dis-
play selected GO enrichments (bottom; log10 p-value; red line, P = 0.05). (C) Venn diagrams show the overlap of genes after acute or chronic I-BET858 
treatment. Statistics: 2 test, ***, P < 0.0001; OR, 247 and 124.8.
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The key behavioral symptoms of ASD in humans include ab-
normal social interactions, communication deficits, anxiety 
and repetitive behaviors. A combination of alterations in so-
cial behaviors, anxiety, and repetitive behaviors are therefore 
frequently used to diagnose autism-like phenotypes in mice 
(Peça et al., 2011; Ellegood and Crawley, 2015).
The impact of acute I-BET858 on mouse behavior was 
determined by assessing basal motor activity, anxiety-like be-
haviors, social interaction, and memory (Fig. 5). We did not 
observe any signs of distress, anxiety, or other behavioral or 
motor abnormalities in mice of various ages acutely treated 
with I-BET858 (Fig. 5 A and not depicted). Acute I-BET858 
treatment also did not affect memory formation in mice. 
A single injection of I-BET858, after training mice in a 
similarly controlled by I-BET858 in cultured neurons in vitro. 
The preferential impact of I-BET858 on long genes in neu-
rons may reflect the known role of BET proteins in regula-
tion of transcriptional elongation (Zhou et al., 2012; Patel 
et al., 2013). It is possible that the successful generation of a 
nascent transcript for long genes >100 kb is more susceptible 
to perturbation of elongation efficiency as compared with 
shorter genes.
I-BET858 treatment induces autism-like behavior in mice
The selective impact of BET protein inhibition on neuronal 
gene expression and the preferential I-BET858–dependent 
inhibition of long genes suggested that treatment with I-BET 
may lead to the development of ASD-like behaviors in mice. 
Figure 4. I-BET858–mediated gene suppression correlates with gene length in vitro and in vivo. (A) Distribution of gene expression levels ver-
sus gene length in primary neurons after 2 h (red) or 12 h (blue) I-BET858 or vehicle treatment (2 h, black; 12 h, green) using microarray analysis (n = 3). 
Linear regression of log2 gene expression fold changes (middle) and running averages (right) are shown (Pearson’s r = 0.147877, red line; P < 
0.0001). (B) Bar graph shows average gene length of I-BET858–induced (red) or –suppressed (blue) genes after 12 h using microarray analysis (n = 3); 
dashed line, average neuronal gene length. (C) Distribution of gene expression versus gene length in primary neurons after 12-h treatment with BNDF 
(red), vehicle (black), I-BET858 (green), or BDNF + I-BET858 (blue) using microarray analysis (n = 3) is shown. Linear regression (middle) and running aver-
ages (right) of log2 expression fold changes of 12-h BDNF induced genes ± I-BET are shown (Pearson’s r = 0.119946, red line; P = 0.004). (D) Bar graph 
shows average gene length of I-BET858–induced (red) and –suppressed (blue) BDNF-inducible genes after 12 h. (E) Distribution of gene expression versus 
gene length using RNA-seq analysis of mouse striatum (n = 2) after acute (left) or chronic (right) I-BET858 treatment are shown. (F) Bar graph shows 
average gene length of I-BET858–induced (red) and –suppressed (blue) genes after acute and chronic I-BET858 treatment, respectively. Statistics: two-
tailed unpaired Student’s t test, error bars represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.
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for social novelty. Preference for social novelty requires func-
tional social recognition and is defined as the test mouse 
spending more time exploring/sniffing a novel mouse than 
a familiar mouse. Unlike vehicle-injected mice, chronic 
I-BET858–treated mice displayed no significant preference 
in exploring a novel mouse over a familiar mouse (Fig. 5 E). 
Importantly, the observed effects on social preference in the 
I-BET858–treated mice are not due to defective olfaction or 
reduced overall explorative activity in the three-chamber 
assay; I-BET858-treated mice displayed no differences in 
hidden food retrieval, no left versus right bias differences, and 
no reduction in velocity, total distance moved, or time spent 
sniffing/exploring during the social interaction paradigm 
(Fig. 5 F and not depicted) as compared with control, vehicle-
injected mice. Notably, mice that were chronically treated 
with I-BET858 between 4–6 wk of age showed a partial re-
versal of the social behavioral deficits with age (Fig. 5 G).
In summary, our findings reveal a key role of BET pro-
teins in the regulation of selected genes that control normal 
neuronal development and function. The significance of BET 
proteins in the regulation of mouse behavior is underscored 
by the development of an ASD-like syndrome in mice treated 
with brain permeable I-BET858. The data also suggest that 
fear-conditioning paradigm, has no effect on mouse memory 
of the foot-shock–associated context or auditory cue 24 h 
later, as compared with vehicle-injected controls (Fig. 5 B).
Contrary to acute BET inhibition, chronic daily I-BET858 
administration starting at 4 wk of age led to the development 
of behavioral abnormalities consistent with an autism-like 
syndrome (Fig. 5, D and E). After 2 wk of chronic I-BET858 
treatment, 6-wk-old mice displayed reduced explorative 
motor activity and heightened anxiety-like behavior in the 
open field (Fig. 5 D). I-BET858–treated mice also spend 
slightly more time engaging in stereotypic behaviors as com-
pared with their vehicle-treated controls (Fig. 5 D). Using 
the three-chamber social approach task that is commonly 
used to reveal ASD-like social deficits in mice (Ellegood and 
Crawley, 2015), we found that chronic (Fig. 5 E), but not 
acute (Fig. 5 C), 6-wk-old I-BET858–treated mice displayed 
greatly reduced sociability. When tested for their prefer-
ence to explore a novel mouse versus an inanimate novel object, 
the chronic I-BET858–treated mice spent equal amounts of 
time sniffing the mouse and the object, unlike vehicle-treated 
littermates that prefer to explore the novel mouse (Fig. 5 E). 
In addition to the reduced sociability, chronic I-BET858–
treated mice showed a significant reduction in their preference 
Figure 5. I-BET858 treatment induces an autism-like syndrome in mice. (A–C) Effects of acute I-BET858 treatment on motor activity and explora-
tion in the open field (A; n = 8 mice per group), memory (B; n = 10), and social interaction (C; n = 8) in mice are shown. (D and E) Effects of chronic  
I-BET858 treatment on motor activity, anxiety, and stereotypic behavior in the open field (D; n = 10), social behavior (E; n = 10), hidden food retrieval  
(F; n = 5), left versus right bias and total distance moved during the social interaction paradigm (n = 10) in mice are shown. (G) Social behavior in mice  
5 mo after chronic I-BET858 treatment is shown (n = 5). Statistics: Student’s t test, error bars represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.
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embryos per experiment were collected through an incision of the mother’s 
abdomen, taken out of the amniotic sacs, and decapitated in ice-cold Hank’s 
Balanced Salt Solution (HBSS). Using fine scissors and forceps, brains were 
rapidly dissected and the cortex cleared from meninges and isolated under a 
dissection microscope. Cortices were collected in ice-cold HBSS and kept 
on ice until all embryos had been dissected. In a tissue culture hood, HBSS 
was removed and the cortex tissue was digested by 0.25% Trypsin-EDTA 
for 12 min at 37°C, followed by DNase1 treatment for 10 min at 37°C. The 
tissue was dissociated by serial trituration with a 25-ml serological pipette, 
followed by trituration with 10 and 5 ml serological pipettes. Cell suspension 
was washed once with DMEM medium, supplemented with 10% FBS and 
1% penicillin/streptomycin, and passed through a 40 µM cell strainer before 
being counted on a hemocytometer. Single cells were seeded on poly-d-
lysine (0.1 mg ml1)–coated wells at a density of 106 cells per well on a 
12-well plate. Cells were grown in neurobasal medium, complemented with 
B27 supplement, N2 supplement, and 0.5 mM l-glutamine and maintained 
at 37°C in 5% CO2 for 1 wk. Cultures were treated with DMSO (0.2%), 
I-BET858 (1 µM, 0.2% DMSO), BDNF (50 ng/ml), or BDNF + I-BET858 
for 2 and 12 h on day 7 in vitro. Cultures were washed with PBS on ice and 
processed for RNA isolation using TRIzol/Chloroform extraction.
In vivo I-BET858 treatment
I-BET858 solutions used for in vivo studies (3 mg/ml) were prepared in 10% 
Kleptose buffer with 5% DMSO (pH 6.5) and maintained at 4°C. I-BET858 
was made fresh daily; buffers were made fresh each week. 30 mg/kg 
I-BET858 or vehicle (Kleptose buffer, pH 6.5) was delivered by i.p injec-
tion. For acute treatment, 6-wk-old mice received a single I-BET858 injec-
tion. For chronic I-BET858 treatment, 4-wk-old mice received a total of 14 
i.p. injections (1/d) over 2 wk. Gene expression and behavioral changes 
were assessed in 6-wk-old mice at 4 h (acute, n = 8–10 for behavior, n = 2 
for gene expression analysis) or 12 h (chronic, n = 10 for behavior, n = 2 for 
gene expression analysis) after the (final) I-BET858 injection, respectively.
RNA isolation
For in vitro gene expression analysis, neuronal culture plates were washed 
once with PBS, and TRIzol was added directly to cultures to isolate RNA 
(n = 3 per group). For in vivo gene expression analysis, mice were anesthe-
tized with CO2 and decapitated. The striata from two control and acute or 
chronic I-BET–treated mice were rapidly dissected on ice and frozen in liq-
uid nitrogen. RNA extraction from frozen samples was performed using 
TRIzol/Chloroform according to manufacturer’s instructions (Invitrogen). 
RNA was precipitated overnight at 80°C in isopropanol with 0.15 M so-
dium acetate, washed twice with 70% ethanol, air-dried, and resuspended in 
RNase-free water. RNA samples were purified using RNeasy Micro col-
umns (QIAGEN) with on-column DNase treatment as specified by manu-
facturer. RNA integrity was assayed using nanodrop and RNA Pico chip on 
Bioanalyzer 2100 (Agilent) for quality RIN > 9.
Microarray analysis
Total RNA samples were prepared for microarray analysis as described pre-
viously (Schaefer et al., 2009). In brief, total RNA was converted to cDNA 
using the Superscript GeneChip Expression 3-Amplification Reagents Two-
Cycle cDNA Synthesis kit (Affymetrix) and the GeneChip T7-Oligo(dT) 
Primer. Affymetrix Mouse Genome 430 2.0 arrays were used in all experi-
ments. Mouse Genome 430 2.0 arrays were scanned using the GeneChip 
Scanner 3000 (Affymetrix) and globally scaled to 150 using the Affymetrix 
GeneChip Operating Software (GCOS v1.4). Three biological replicates 
were performed for each experiment. GeneChip CEL files were imported 
into GeneSpring GX 13.0 (Agilent Technologies), processed with the GC-
RMA algorithm, and expression values on each chip were normalized to 
that chip’s 50th percentile. Statistical analysis was performed to determine 
which genes are differentially expressed in BDNF-, I-BET858-, or BDNF + 
I-BET858–treated neurons as compared with the DMSO controls. Genes 
were filtered for a raw expression level of >20 and a fold change of >2, 
followed by moderate t test with a p-value cutoff of 0.05. P values were 
environmental factors that have the ability to affect BET pro-
tein function or BET target gene expression may contribute 
to ASD. The pharmacological induction of ASD-like symp-
toms in mice provides a valuable tool for the identification of 
genes that may play a pivotal role in the etiology of the dis-
ease or for the development of novel drugs targeting ASD. 
Moreover, our studies suggest that the pharmacological control 
of BET proteins or BET-dependent gene expression regula-
tion could be used not only for modeling of autism-like be-
haviors, but possibly for the correction of aberrantly expressed 
genes in ASD and other neurodevelopmental disorders.
MATERIALS AND METHODS
Animals
4-wk-old male C57BL/6 mice were purchased from The Jackson Labora-
tory. Mice were housed at five animals per cage on a 12-h light/dark cycle 
(lights on from 0700 to 1900 h) at constant temperature (23°C) with ad libi-
tum access to food and water. All studies were conducted in accordance with 
the GSK Policy on the Care, Welfare, and Treatment of Laboratory Animals 
and were reviewed by the Institutional Animal Care and Use Committee at 
GSK and the IACUC at Icahn School of Medicine at Mount Sinai where 
the work was performed.
BET inhibitors
Inhibitor characterization. Fluorescence resonance energy transfer (FRET), 
surface plasmon resonance (SPR), and lipopolysaccharide-stimulated IL-6 
cytokine production from human peripheral blood mononuclear cells 
(PBMCs) or whole blood (WB) to compare potencies of I-BET858, 
I-BET762, and I-BET151 was performed as previously described (Dawson 
et al., 2011).
In vivo pharmacokinetics. I-BET858 penetration in mouse brain tissue 
was determined 4 h after a single I-BET858 i.p. injection of 30 mg/kg (n = 
3 mice), and after continuous i.v. infusion to steady state at 0.35 mg/kg in 
rat. Pharmacokinetics were determined in mouse after i.p. injection at 3 and 
30 mg/kg (n = 3 mice) and in rat after 1-h continuous i.v. infusion at 1 or 
5 mg/kg p.o. administration (n = 3 rats). For time course measurements, 
mouse whole trunk blood and brain tissues were collected at 2, 16, and 26 h 
after a single injection of 30 mg/kg I-BET858 (n = 4–10/time point).
BRD4-BD1/ligand cocrystallization and x-ray structure determi-
nation. BRD4-BD1 protein was produced for crystallographic studies as 
previously described (Nicodeme et al., 2010). BRD4-BD1 ligand complex 
was cocrystallized with at least 3:1 excess of compound at 9 mg/ml in 120 nl + 
120 nl sitting drops using a 96-well MRC plate with a well solution of 
0.1 M MIB (pH 4.0) 25% PEG1500 at 20°C and cryoprotected by adding 
20% ethylene glycol before flash freezing in liquid nitrogen. Data from a sin-
gle crystal was collected at the European Synchotron Radiation Facilities 
(Grenoble) and processed to 2.01 Å using XDS and AIMLESS within 
AUTOPROC (Vonrhein et al., 2011). Manual model building was performed 
using COOT (Emsley and Cowtan, 2004) and refined using REFMAC 
within the CCP4 suite of software (Project, 1994). The final crystal structures 
were deposited in the Protein Data Bank under the accession code 5acy.
Bromodomain profiling. Bromodomain profiling was provided by 
DiscoveRx Corp. on the basis of BROMOscan. This screen accounted for 
the determination of the Kd between I-BET858 and each of the 34 DNA-
tagged bromodomains included in the assay, by binding competition against 
a reference immobilized ligand (DiscoveRx; Theodoulou et al., 2015).
Primary cortical neuron culture
Embryonic day 18 (E18) timed-pregnant female mice were anesthetized 
with CO2 and sacrificed by cervical dislocation. In a dissection hood, 24–26 
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For all behavioral experiments, experimenters were blinded to the treat-
ment of the animals. GraphPad Prism version 5.01 for Windows (Graph-Pad 
Software) was used for statistical analysis of the data. Samples corresponding 
to data points that are more than two standard deviations from the sample 
mean were excluded from analyses. All procedures were conducted in strict 
accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and were approved by the IACUC at Icahn 
School of Medicine at Mount Sinai.
Locomotion and exploration. Locomotion, exploratory, and thigmotaxis/
anxiety behavior was measured using the open field analysis as previously 
described (Schaefer et al., 2009). Mice were assessed for 60 min and data 
were collected in 5-min intervals (n = 10). Locomotor activity was assessed 
by total distance traveled (m), anxiety-like behavior was defined by counts 
of rearing (number of vertical episodes in counts), and the ratio of the 
distance moved in the center versus the periphery (thigmotaxis), and 
stereotypical behavior (time spent). Mice were tested in the open field 
4 h after acute (n = 8) and 12 h after chronic (n = 10) I-BET858 or 
vehicle treatment.
Memory and learning. Memory and learning in mice acutely treated with 
I-BET858 or vehicle (n = 10) was analyzed using a standard fear condition-
ing paradigm (Med Associates) as described previously (Schaefer et al., 2009). 
In brief, a mouse was placed in the test chamber (house lights on) and 
allowed to explore freely for 2 min. A white noise (80 dB) was then pre-
sented for 30 s, coterminating with a mild foot shock (2 s, 0.5 mA). 2 min 
later, the same sequence of auditory cue-shock pairing was repeated. The 
mouse was removed from the chamber 30 s later and returned to its home 
cage. Freezing behavior was continuously recorded during the time spent in 
the test chamber. Mice were injected with either I-BET858 (30 mg/kg) or 
vehicle 10 min after the training. 24 h later, the mouse was placed back into 
the test chamber for 5 min and freezing behavior was recorded (context test). 
2 h later, the mouse was tested for freezing in response to the auditory cue. 
Environmental and contextual cues were changed for the auditory cue test. 
The auditory cue test was divided into two phases: 3 min in the absence of 
the auditory cue and 3 min of the auditory cue. The time freezing during 
each test was converted to a percentage of freezing value.
Social interaction paradigm. Social preference and social memory was 
performed as previous described (Ellegood and Crawley, 2015) using a Plexi-
glas chamber divided into three compartments. The two edge compartments 
contain an empty wire cup. Mice were habituated to the testing room for at 
least 1 h before the experiment. Stimulus mice are 6–8-wk-old C67Bl/6 
male mice that were housed in separate areas of the animal facility and had 
no prior contact with the test mice. Stimulus mice were habituated to the 
wire cup before testing. For the sociability test, the test mouse is introduced 
to the middle chamber and allowed to freely move and habituate to all three 
compartments for 10 min. Then, the mouse was restricted to the middle 
chamber using the dividers, while a novel object (Lego) was placed under the 
wire cup in one chamber and an unfamiliar mouse in the other. The test 
mouse was then allowed to investigate the whole apparatus for 10 min. After, 
the mouse was again restricted to the middle chamber while the object was 
replaced by a second, unfamiliar mouse. The test mouse was allowed 10 min 
to investigate. Data were acquired using the Ethovision system (Noldus) to 
automatically track motion while manual scoring was used to quantify time 
spent sniffing the stimuli. Counterbalancing was used to control for potential 
left-right preferences.
Olfaction. Olfaction was tested by exposing mice (n = 5) to a small amount 
of palatable food (Cinnamon Toast Crunch cereal; General Mills) once per 
day for 2 d. Mice were deprived of food overnight before the test. A clean 
cage was filled with roughly 3 inches of fresh bedding, and the stimulus food 
was buried in the bedding until it was not visible. Mice were then placed in 
the cage one at a time and allowed to freely explore. The latency to localize 
and retrieve the food was measured. All mice retrieved the food within 2 min. 
adjusted using the Benjamini-Hochberg correction. Gene expression changes 
are shown using Volcano plots where the corrected P value (-log10) is plot-
ted versus fold-change (log2). Heatmaps were created by hierarchical gene 
clustering on entities using the Euclidean distance metric and the Ward’s 
linkage rule using GeneSpring GX 13.0.
RNA sequencing
Double-stranded cDNA was generated from 1–5 ng purified RNA using 
Ovation V2 kit (NuGEN) following manufacturer’s instructions. 500 ng of 
cDNA per sample were sonicated to obtain fragments of 200 bp using Covaris-
S2 system (duty cycle,10%; intensity, 5.0; Bursts per second, 200; duration, 
120 s; mode, frequency sweeping; power, 23 W; temperature, 5.5–6°C; 
Covaris Inc.). These fragments were then used to produce sequencing librar-
ies with the TruSeq DNA Sample kit (Illumina). The quality of the libraries 
was ensured using the 2200 TapeStation (Agilent). Duplexed libraries were 
sequenced on HiSeq 2000, typically yielding on average 60 million, 100-bp-
long single-end reads per sample (Illumina). All samples were mapped at a 
rate of 79–80%. After filtering out adaptor and low-quality reads, reads were 
mapped using TopHat (version 2.0.8) to the mm9 mouse genome. The 
Cufflinks/Cuffdiff suite was used to estimate gene-level expression values as 
fragments per kilobase of exon model per million mapped fragments (FPKM). 
Differentially expressed autosomal genes between control and acute I-BET858 
or chronic I-BET858 libraries were determined using a p-value <0.05 and 
fold change >2. Values with a FPKM <0.5 were excluded.
Gene list statistics
Overlaps between gene sets were tested for statistical significance using the 
2 test by using GraphPad Prism 5.01. The total number of expressed genes 
in neurons as measured by microarray (25,788) was used to calculate the 2 
test for all lists generated by microarray. For RNA sequencing data, the total 
number of protein-coding genes in the mouse genome according to Mouse 
Genome Informatics (24,979) was used for the 2 test. The ASD candidate 
gene list (n = 1193) was obtained from the SFARI homepage (Basu et al., 
2009) and supplemented with the list from (King et al. (2013; Table S1).
Pathway analysis
Bioinformatic network and pathway analyses of I-BET858–suppressed genes 
have been performed using the Database for Annotation, Visualization, and 
Integrated Discovery (DAVID) version 6. Representative biological path-
ways from the top 25 enriched categories are shown. Pathway enrichment 
was calculated as log10 p-value. The p-value cut-off (0.05) for significance 
is indicated by red dashed line.
Gene length analysis
Gene symbols were annotated with their gene start and end (in bp) using the 
mm9 database. Gene length was then calculated from these values. Replicate 
symbols were filtered out. To determine the relationship between fold-
change (e.g., I-BET858 vs. DMSO) and gene length, the log2 fold-change 
was plotted versus length for all genes expressed in neurons. Pearson correla-
tion coefficients and P values were calculated from the resulting scatter plot 
using linear regression. Genes were binned by length and a sliding window 
was used to calculate the average of the log2 fold changes for the genes within 
each length window (in vitro: window, 200 bp, step, 40 bp; in vivo: window, 
800 bp, step, 20 bp). For the BDNF-induced, I-BET858–suppressed gene list, 
different parameters were necessary due to the significantly smaller list size 
(625 genes; window, 80 bp, step, 1 bp). To assess changes in gene expression 
levels in regards to length, raw microarray values were transformed using 
log10 and plotted versus length for each condition. A running average was 
calculated using window size of 400 bp and a step size of 20 bp. The code 
used to generate expression versus length plots can be found at https://github 
.com/GeneExpressionScripts/ibet858_expression_plots.
Behavioral analysis
All behavioral tests were performed on 6-wk-old adult C57BL/6 males (n = 
8–10; The Jackson Laboratory) and were performed between 0700 and 1900 h. 
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